Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Novagold Resources Inc. (NG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Novagold Resources Inc. — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.13 (market cap $6.43B), while Novagold Resources Inc. trades at $6.37 (market cap $2.73B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 2.4× Novagold Resources Inc.'s market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Novagold Resources Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 1 Days and Novagold Resources Inc. for 0 Days on average.
| IOVA | NG | |
|---|---|---|
Market Cap | $6.43B | $2.73B |
Volume | 10,599,472 | 6,599,188 |
Sector | Health | Basic Materials |
52-Week High | $14.82 | $14.20 |
52-Week Low | $1.81 | $5.18 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $6.37B | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Iovance Biotherapeutics (IOVA) trades at $14.50, down 0.41% on the day, with a bullish technical signal from moving averages. The company shows strong revenue growth, with 2026 guidance raised to $410–420 million, but remains unprofitable with a net income margin of -89.09%. Recent news highlights institutional buying and positive analyst sentiment driven by accelerating adoption of its Amtagvi therapy.
The outlook is optimistic due to expanding TIL therapy applications and raised revenue guidance, but high cash burn and lack of profitability pose significant risks. Analyst consensus is strongly bullish with a $13.44 price target, though the stock faces volatility from clinical trial outcomes and competitive pressures.
NovaGold Resources (NG) trades at $6.63, down 1.49% today, as the company navigates its development phase for the Donlin Gold project. The stock shows mixed earnings performance with recent quarterly losses but beats expectations in two of the last four quarters. Financials reveal negative profitability metrics with ROE at -32.81% and net income of -$94.66M for 2025, though cash flow remains positive due to financing activities. Recent news highlights the company's move to acquire full ownership of Donlin Gold, a major Alaska gold project.
The outlook for NG hinges on successful development of Donlin Gold, with 100% analyst buy ratings signaling strong Wall Street confidence. However, significant execution risks exist given negative earnings and substantial capital requirements. Investors face volatility from gold price fluctuations and project development timelines, making this suitable for those with high risk tolerance seeking exposure to a major gold development story.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Novagold Resources Inc.
NovaGold Resources Inc. is a mineral exploration and development company that holds a majority interest in the Donlin Gold project, an undeveloped gold deposit in Alaska.
Read more on NG →
